Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
- 1 April 1999
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 6 (4) , 606-615
- https://doi.org/10.1038/sj.gt.3300841
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 46 references indexed in Scilit:
- Failure of TGF β1 and IL‐12 to regulate human FasL and mTNF alloreactive cytotoxic T‐cell pathwaysTissue Antigens, 1998
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997
- Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cellsGene Therapy, 1997
- Radiologic Assessment of Intranodal Vascularity in Head and Neck Squamous Cell CarcinomaInvestigative Radiology, 1996
- Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12Human Gene Therapy, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- The Current Status of Ultrasound and Color Doppler Imaging in Screening for Ovarian CancerGynecologic Oncology, 1994
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.The Journal of Experimental Medicine, 1993
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990